This content is first seen at HSA
Disclaimer: The information provided in this site is correct at the time of publication. POMConnect assumes no responsibility or liability for any errors or omissions in the content of this site.
| Product Name | DUPIXENT SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 300MG/2ML |
| Active Ingredient | Dupilumab |
| Product Registrant | SANOFI-AVENTIS SINGAPORE PTE LTD |
| Date of Approval | 04/06/2023 |
| Indications: 1.4 Prurigo Nodularis DUPIXENT is indicated for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. | |
| Product Name | IDACIO SOLUTION FOR INJECTION IN PRE-FILLED PEN 40MG/0.8MLIDACIO SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 40MG/0.8MLIDACIO SOLUTION FOR INJECTION FOR PAEDIATRIC USE 40MG/0.8ML VIAL |
| Active Ingredient | Acdalimumab |
| Product Registrant | FRESENIUS KABI (SINGAPORE) PTE LTD |
| Date of Approval | 13/06/2023 |
| Indications: Pediatric Ulcerative Colitis IDACIO is indicated for inducing and maintaining clinical remission in pediatric patients 5 years of age or older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. | |
| Product Name | AMGEVITA SOLUTION FOR INJECTION IN PREFILLED SYRINGE 20MG/0.4ML AND 40MG/0.8MLAMGEVITA SOLUTION FOR INJECTION IN PREFILLED AUTOINJECTOR 40MG/0.8ML |
| Active Ingredient | Adalimumab |
| Product Registrant | AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD |
| Date of Approval | 05/06/2023 |
| Indications: Pediatric Ulcerative Colitis AMGEVITA is indicated for inducing and maintaining clinical remission in pediatric patients 5 years of age or older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. | |
| Product Name | ABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 20 MG/0.4 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED PEN 40 MG/0.8 MLABRILADA SOLUTION FOR INJECTION IN SINGLE-DOSE PREFILLED SYRINGE 40 MG/0.8 ML |
| Active Ingredient | Adalimumab |
| Product Registrant | PFIZER PRIVATE LIMITED |
| Date of Approval | 16/06/2023 |
| Indications: Paediatric ulcerative colitis ABRILADA is indicated for inducing and maintaining clinical remission in paediatric patients 5 years of age or older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. | |
| Product Name | SCEMBLIX FILM-COATED TABLET 20 MGSCEMBLIX FILM-COATED TABLET 40 MG |
| Active Ingredient | Asciminib hydrochloride |
| Product Registrant | NOVARTIS (SINGAPORE) PTE LTD |
| Date of Approval | 22/06/2023 |
| Indications: Adult patients with philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), harboring the T315I mutation. | |
Link to the original news (HSA) :
